CNTX Stock Price | Context Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Context Therapeutics Inc • CNTX

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Context Therapeutics Inc

Ticker

CNTX

Trading on

NASDAQ

ISIN

US21077P1084

Industry

Biotechnology

Sector

Healthcare

CEO

Martin A. Lehr

Headquarters

2001 Market Street, Philadelphia, PA, United States, 19103

Employees

Website

contexttherapeutics.com

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Metrics

BasicAdvanced

Market cap

$100M

P/E ratio

EPS

-$0.24

Dividend Yield

0.00%

Beta

1.94

Forward P/E ratio

EBIDTA

$-30.2M

Ex dividend date

Price & volume

Market cap

$100M

Average daily volume

0.4M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

1.37

Earnings

EPS

-$0.24

EPS estimate (current quarter)

-$0.09

EPS estimate (next quarter)

-$0.10

EBITDA

$-30.2M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.94

52-week High

$1.61

52-week Low

$0.49

50-day moving average

$1.15

200-day moving average

$0.86

Short ratio

1.78

Short %

0.91%

Management effectiveness

ROE (TTM)

-33.68%

ROA (TTM)

-22.81%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

91.9M

Float

51M

Insiders %

2.27%

Institutions %

75.36%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 5 analysts.

Average price target

$5.33

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.03

-$0.06

47.09%

Q4 • 24Beat

-$0.05

-$0.12

58.33%

Q1 • 25Beat

-$0.09

-$0.06

-52.03%

Q2 • 25Missed

-$0.10

-$0.09

-11.11%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-8.8M

-∞%

Q2 • 25

$0M

$-9.7M

-∞%

Q3 • 25

NaN%

9.81%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$87.2M

$4.6M

5.29%

Q2 • 25

$79.2M

$6.1M

7.64%

Q3 • 25

-9.09%

31.45%

44.59%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-5.8M

$0M

$-5.8M

Q2 • 25

$-6.6M

$0M

$-6.6M

Q3 • 25

12.74%

NaN%

12.74%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Context Therapeutics Inc share?

Context Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Context Therapeutics Inc have?

Context Therapeutics Inc currently has 91.9M shares.

Does Context Therapeutics Inc pay dividends?

No, Context Therapeutics Inc doesn't pay dividends.

What is Context Therapeutics Inc 52 week high?

Context Therapeutics Inc 52 week high is $1.61.

What is Context Therapeutics Inc 52 week low?

Context Therapeutics Inc 52 week low is $0.49.

What is the 200-day moving average of Context Therapeutics Inc?

Context Therapeutics Inc 200-day moving average is $0.86.

Who is Context Therapeutics Inc CEO?

The CEO of Context Therapeutics Inc is Martin A. Lehr.

How many employees Context Therapeutics Inc has?

Context Therapeutics Inc has 12 employees.

What is the market cap of Context Therapeutics Inc?

The market cap of Context Therapeutics Inc is $100M.

What is the P/E of Context Therapeutics Inc?

The current P/E of Context Therapeutics Inc is null.

What is the EPS of Context Therapeutics Inc?

The EPS of Context Therapeutics Inc is -$0.24.

What is the PEG Ratio of Context Therapeutics Inc?

The PEG Ratio of Context Therapeutics Inc is null.

What do analysts say about Context Therapeutics Inc?

According to the analysts Context Therapeutics Inc is considered a buy.